Kelly Logue

Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors

Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers et al. · Journal of Medicinal Chemistry · 2000 · 301 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy

Lee T. Bacheler, Susan Jeffrey, George J. Hanna et al. · Journal of Virology · 2001 · 240 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues

George V. De Lucca, Ui T. Kim, Jing Liang et al. · Journal of Medicinal Chemistry · 1998 · 50 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Synthesis, antiviral activity and pharmacokinetics of P1/P1′ substituted 3-aminoindazole cyclic urea HIV protease inhibitors

Robert F. Kaltenbach, Mona Patel, Robert E. Waltermire et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Improved P1/P1‘ Substituents for Cyclic Urea Based HIV-1 Protease Inhibitors:  Synthesis, Structure−Activity Relationship, and X-ray Crystal Structure Analysis

David A. Nugiel, Kim Jacobs, Lyndon A. M. Cornelius et al. · Journal of Medicinal Chemistry · 1997 · 27 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17